ATR

AptarGroup (NYSE:ATR) reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower margins in Beauty and Closures weighed on results.

AptarGroup (ATR) delivered earnings and revenue surprises of +4.11% and +4.40%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

(ATR) on Thursday reported third-quarter earnings of $32.The Crystal Lake, Illinois-based company said it had profit of 51 cents per share.

AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

What the Massachusetts General Hospital partnership means for AptarGroup AptarGroup (ATR) has moved to deepen its presence in nose to brain drug delivery through a research agreement with Massachusetts General Hospital, centered on the Stanton Lab’s work on neurological disease treatments.

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse…